Granted Patent B2

US 12,239,689 · App. 17/839,390 · Granted Mar 4, 2025

Inventors: Kennett Sprogøe (Holte, DK); Harald Rau (Dossenheim, DE); Felix Cleemann (Mainz, DE); Ulrich Hersel (Heidelberg, DE)

Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S

A61K38/22A61K47/60

Abstract

Claims (64)

1. A method of treating, controlling, or delaying a mammalian patient in need of the treatment one or more diseases which can be treated with a C-type natriuretic peptide (CNP), comprising the step of subcutaneously administering to said patient in need thereof a therapeutically effective amount of a controlled-release CNP agonist or a pharmaceutical composition comprising a controlled-release CNP agonist and at least one excipient, wherein the controlled-release CNP agonist is of formula (Ia) or (Ib):

wherein

-D is a CNP moiety comprising a ring moiety, wherein the ring moiety has the amino acid sequence of SEQ ID NO:96, provided the methionine at position 11 of SEQ ID NO:96 can be substituted with asparagine, the ring moiety being between two cysteine residues forming a disulfide bridge, wherein the CNP moiety has the amino acid sequence of SEQ ID NO:24, SEQ ID NO: 25 or SEQ ID NO:30; is a reversible prodrug linker, which is cleavable in aqueous buffer at pH 7.4 and 37° C. in the absence of enzymes with a half-life of up to six months, and which is covalently and reversibly conjugated to the side chain of an amino acid residue of the ring moiety of -D or to the backbone of the ring moiety of -D;

wherein -L 1 - has the formula (II):

wherein the dashed line indicates the attachment to a nitrogen of -D by forming an amide bond;

—X— is —C(R 4 R 4a )—; —N(R 4 )—; —O—; —C(R 4 R 4a )—C(R 5 R 5a )—; —C(R 5 R 5a )—C(R 4 R 4a )—; —C(R 4 R 4a )—N(R 6 )—; —N(R 6 )—C(R 4 R 4a )—; —C(R 4 R 4a )—O—; —O—C(R 4 R 4a )—; or —C(R 7 R 7a )—;

>X 1 ═is >C═; or >S(O)═;

—X 2 — is —C(R 8 R 8a )—; or —C(R 8 R 8a )—C(R 9 R 9a )—;

═X 3 is ═O; ═S; or ═N—CN;

—R 1 , —R 1a , —R 2 , —R 2a , —R 4 , —R 4a , —R 5 , —R 5a , —R 6 , —R 8 , —R 8a , —R 9 , —R 9a are independently selected from the group consisting of —H; and C 1-6 alkyl;

—R 3 , —R 3a are independently selected from the group consisting of —H; and C 1-6 alkyl, provided that in case one of —R 3 , —R 3a or both are other than —H they are connected to N to which they are attached through an sp 3 -hybridized carbon atom;

—R 7 is —N(R 10 R 10a ); or —NR 10 —(C═O)—R 11 ;

—R 7a , —R 10 , —R 10a , —R 11 are independently of each other —H; or C 1-6 alkyl;

optionally, one or more of the pairs —R 1a /—R 4a , —R 1a /—R 5a , —R 1a /—R 7a , —R 4a /—R 5a , —R 8a /—R 9a form a chemical bond;

optionally, one or more of the pairs —R 1 /—R 1a , —R 2 /—R 2a , —R 4 /—R 4a , —R 5 /—R 5a , —R 8 /—R 8a , —R 9 /—R 9a are joined together with the atom to which they are attached to form a C 3-10 cycloalkyl; or 3- to 10-membered heterocyclyl;

optionally, one or more of the pairs —R 1 /—R 4 , —R 1 /—R 5 , —R 1 /—R 6 , —R 1 /—R 7a , —R 4 /—R 5 , —R 4 /—R 6 , —R 8 /—R 9 , —R 2 /—R 3 are joined together with the atoms to which they are attached to form a ring A;

optionally, —R 3 /—R 3a are joined together with the nitrogen atom to which they are attached to form a 3- to 10-membered heterocycle;

A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C 3-10 cycloalkyl; 3- to 10-membered heterocyclyl; and 8- to 11-membered heterobicyclyl; and

wherein —L 1 — is substituted with —L 2 —Z provided that the hydrogen marked with the asterisk in formula (II) is not replaced by —L 2 —Z;

—L 2 — is a single chemical bond or a spacer moiety;

—Z is a water-soluble carrier moiety comprising a moiety of formula (a):

wherein

the dashed line indicates attachment to —L 2 —;

BPa is a branching point selected from the group consisting of —N<, —CR< and >C<;

—R is selected from the group consisting of —H and C 1-6 alkyl;

a is 0 if BP a is —N< or —CR< and a is 1 if BP a is <C<;

—S a —, —S a′ —, —S a″ — and —S a′″ — are independently of each other a chemical bond or are selected from the group consisting of C 1-50 alkyl, C 2-50 alkenyl, and C 2-50 alkynyl;

wherein C 1-50 alkyl, C 2-50 alkenyl, and C 2-50 alkynyl are optionally substituted with one or more —R 1 , which are the same or different and wherein C 1-50 alkyl, C 2-50 alkenyl, and C 2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of —T—, —C(O)O—, —O—,

—C(O)—, —C(O)N(R 2 )—, —S(O) 2 N(R 2 )—, —S(O)N(R 2 )—,

—S(O) 2 —, —S(O)—, —N(R 2 )S(O) 2 N(R 2a )—, —S—, —N(R 2 )—, —OC(OR 2 )(R 2a )—,

—N(R 2 )C(O)N(R 2a )—, and —OC(O)N(R 2 )—;

each —T— is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C 3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each —T—is independently optionally substituted with one or more —R 1 , which are the same or different;

each —R 1 is independently selected from the group consisting of halogen, —CN, oxo (═O),

—COOR 3 , —OR 3 , —C(O)R 3 , —C(O)N(R 3 R 3a ), —S(O) 2 N(R 3 R 3a ),

—S(O)N(R 3 R 3a ), —S(O) 2 R 3 , —S(O)R 3 , —N(R 3 )S(O) 2 N(R 3a R 3b ), —SR 3 , —N(R 3 R 3a ),

—NO 2 , —OC(O)R 3 , —N(R 3 )C(O)R 3a , —N(R 3 )S(O) 2 R 3a , —N(R 3 )S(O)R 3a ,

—N(R 3 )C(O)OR 3a , —N(R 3 )C(O)N(R 3a R 3b ), —OC(O)N(R 3 R 3a ), and C 1-6 alkyl; wherein C 1-6 alkyl is optionally substituted with one or more halogen, which are the same or different;

each —R 2 , —R 2a , —R 3 , —R 3a and —R 3b is independently selected from the group consisting of —H, and C 1-6 alkyl, wherein C 1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and

—P a′ , —P a″ and —P a′″ are independently a polymeric moiety comprising a PEG-based moiety;

x is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16;

y is an integer selected from the group consisting of 1, 2, 3, 4 and 5; and

wherein D-H is released from the controlled-release CNP agonist by cleavage of the linker with a release half-life of at least 6 hours in aqueous buffer at pH 7.4 and 37° C. in the absence of enzymes and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding D-H, and wherein the one or more diseases which can be treated, controlled, or delayed with CNP is selected from the group consisting of achondroplasia, hypochondroplasia, Noonan syndrome and SHOX deficiency.

2. The method of claim 1 , wherein the controlled-release CNP agonist has an EC 50 that is at least 50-fold higher than the EC 50 of D-H.

3. The method of claim 1 , wherein the controlled-release CNP agonist has an EC 50 that is at least 100-fold higher than the EC 50 of D-H.

4. The method of claim 1 , wherein the D-His released with a release half-life of at least 24 hours.

5. The method of claim 1 , wherein the D-H is released with a release half-life of at least 168 hours.

6. The method of claim 1 , wherein the disease is achondroplasia.

7. The method of claim 1 , wherein the CNP moiety has the amino acid sequence of SEQ ID NO:24.

8. The method of claim 1 , wherein the polymer is a branched polymer having a molecular weight of at least 20 kDa.

9. The method of claim 1 , wherein the polymer is a branched polymer having a molecular weight of at least 30 kDa.

10. The method of claim 1 , wherein the polymer is of formula (g):

wherein

the dashed line indicates attachment to -L2-;

—S g —, —S g ′— and —S g ″— are independently selected from the group consisting of C 1-50 alkyl, C 2-50 alkenyl, and C 2-50 alkynyl; wherein C 1-50 alkyl, C 2-50 alkenyl, and C 2-50 O alkynyl are optionally substituted with one or more —R 1 , which are the same or different and wherein C 1-50 alkyl, C 2-50 alkenyl, and C 2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R 2 )—, —S(O) 2 N(R 2 )—, —S(O)N(R 2 )—, —S(O) 2 —, —S(O)—, —N(R 2 )S(O) 2 N(R 2a )—, —S—, —N(R 2 )—, —OC(OR 2 )(R 2a )—, —N(R 2 )C(O)N(R 2a )—, and —OC(O)N(R 2 )—;

each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C 3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more —R 1 , which are the same or different;

each —R 1 is independently selected from the group consisting of halogen, —CN, oxo (═O), —COOR 3 , —OR 3 , —C(O)R 3 , —C(O)N(R 3 R 3a ), —S(O) 2 N(R 3 R 3a ), —S(O)N(R 3 R 3a ), —S(O) 2 R 3 , —S(O)R 3 , —N(R 3 )S(O) 2 N(R 3a R 3b ), —SR 3 , —N(R 3 R 3a ), —NO 2 , —OC(O)R 3 , —N(R 3 )C(O)R 3a , —N(R 3 )S(O) 2 R 3a , —N(R 3 )S(O)R 3a , —N(R 3 )C(O)OR 3a , —N(R 3 )C(O)N(R 3a R 3b ), —OC(O)N(R 3 R 3a ), and C 1-6 alkyl; wherein C 1-6 alkyl is optionally substituted with one or more halogen, which are the same or different;

each —R 2 , —R 2a , —R 3 , —R 3a and —R 3b is independently selected from the group consisting of —H, and C 1-6 alkyl, wherein C 1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and

—Z a and —Z a ′ are independently

wherein

BP a is a branching point selected from the group consisting of —N<, —CR< and >C<;

a is 0 if BP a is —N< or —CR< and a is 1 if BP a is >C<;

—S a —, —S a ′—, —S a ″— and —S a ′″— are independently of each other a chemical bond or are selected from the group consisting of C 1-50 alkyl, C 2-50 alkenyl, and C 2-50 alkynyl;

wherein C 1-50 alkyl, C 2-50 alkenyl, and C 2-50 alkynyl are optionally substituted with one or more —R 1 , which are the same or different and wherein C 1-50 alkyl, C 2-50 alkenyl, and C 2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R 2 )—, —S(O) 2 N(R 2 )—, —S(O)N(R 2 )—, —S(O) 2 —, —S(O)—, —N(R 2 )S(O) 2 N(R 2a )—, —S—, —N(R 2 )—, —OC(OR 2 )(R 2a )—, —N(R 2 )C(O)N(R 2a )—, and —OC(O)N(R 2 )—; and

—P a ′, —P a ″ and —P a ′″ are independently a polymeric moiety comprising a PEG-based moiety.

Priority Claims (3)

Continuity (2)

References Cited (235)

Cited By (1)

US 12,667,604